Table 1.
Characteristics of registered COVID-19 trials in the WHO International Clinical Trials Registry Platform at the time of analysis (n = 1,568)
| Study characteristics | |
|---|---|
| Region | |
| Asia | 498 (32) |
| Europe | 436 (28) |
| North America | 324 (21) |
| Latin America | 114 (7) |
| Africa | 73 (5) |
| Oceania | 23 (2) |
| Multiple regions | 52 (3) |
| Not reported | 48 (3) |
| Recruitment status | |
| Not recruiting | 643 (41) |
| Recruiting | 878 (56) |
| Completed | 35 (2) |
| Suspended | 6 (0.4) |
| Terminated | 5 (0.3) |
| Withdrawn | 1 (0.1%) |
| With results available | 32 |
| Number of centers | |
| Single center | 735 (47) |
| Multiple centers | 638 (41) |
| Not reported | 195 (12) |
| Study design | |
| Parallel | 1,426 (91) |
| Adaptive | 53 (3) |
| Sequential | 42 (3) |
| Factorial | 29 (1.8) |
| Crossover | 15 (1) |
| Cluster | 3 (0.2) |
| Masking | |
| Open label | 706 (45) |
| Blinded label | 798 (51) |
| Not reported | 64 (4) |
| Study aim | |
| Prevention | 223(14) |
| Treatment | 1,333 (85) |
| Postacute period care | 12 (1) |
| Sample size, median | |
| Trials evaluating preventive interventions | 540 (200–1,600) |
| Trials evaluating treatment | 100 (60–269) |
| Trials evaluating postacute period interventions | 100 (60–121) |
Data are n (%) or median (Q1–Q3).